NEW YORK (GenomeWeb News) — CyBio and Promega plan to co-develop and co-market new high-throughput liquid-handling applications based on CyBio’s liquid-handling instruments, the company said today.
Under the agreement, CyBio and Promega will jointly develop and market validated application protocols for high-throughput screening processes in drug development and life science research.
CyBio said its CyBi-Well pipettor and Promega’s MultiTox kits together create a “robust automation solution” that is user-friendly and easy to implement.
The collaborators also will automate Promega’s cell-based multiplex-assays, which CyBio said increases “data quality in toxicity studies” of drug compounds.
Financial terms of the agreement were not released.